New pneumonia vaccine shows promise in early trial
NCT ID NCT05815264
First seen Jan 08, 2026 · Last updated Jun 16, 2026 · Updated 25 times
Summary
This early-stage trial tested a new 23-valent pneumococcal polysaccharide vaccine in 144 healthy people aged 2 and older. Participants received one dose of either the experimental or a control vaccine. The study checked for side effects and measured immune response through blood tests. Results will help determine if the vaccine is safe and triggers a strong immune response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PNEUMONIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Qi County Center for Disease Control and Prevention
Hebi, Henan, China
Conditions
Explore the condition pages connected to this study.